Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

2,280.00p
   
  • Change Today:
      58.00p
  • 52 Week High: 3,170.00
  • 52 Week Low: 1,966.00
  • Currency: UK Pounds
  • Shares Issued: 66.32m
  • Volume: 447,288
  • Market Cap: £1,512.18m
  • RiskGrade: 128
  • Beta: 0.01

Financial Analysis

Select chart: EPS | Dividend | Revenue

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-22 593.40 48.40 82.70p 30.3 n/a -18% 32.00p 1.3%
30-Jun-23 689.70 39.40 84.80p 25.5 12.8 +2% 32.00p 1.5%
30-Jun-24 668.80 5.50 65.50p 25.2 n/a -23% 32.00p 1.9%
30-Jun-25 672.80 28.50 81.80p 25.0 1.0 +25% 32.00p 1.6%
30-Jun-26 658.10 310.50 110.30p 19.5 0.6 +35% 35.20p 1.6%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-27 665.58 89.11 105.95p 21.5 n/a -4% 36.90p 0.0%
30-Jun-28 677.27 94.38 115.53p 19.7 2.2 +9% 38.52p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 30.33 19.47 25.11 0.80

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Genus Market Data

Currency UK Pounds
Share Price 2,280.00p
Change Today 58.00p
% Change 2.61 %
52 Week High 3,170.00
52 Week Low 1,966.00
Volume 447,288
Shares Issued 66.32m
Market Cap £1,512.18m
Beta 0.01
RiskGrade 128

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
97.15% below the market average97.15% below the market average97.15% below the market average97.15% below the market average97.15% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
64.09% above the market average64.09% above the market average64.09% above the market average64.09% above the market average64.09% above the market average
44.19% above the sector average44.19% above the sector average44.19% above the sector average44.19% above the sector average44.19% above the sector average
Income
91.6% below the market average91.6% below the market average91.6% below the market average91.6% below the market average91.6% below the market average
50% below the sector average50% below the sector average50% below the sector average50% below the sector average50% below the sector average
Growth
72.27% above the market average72.27% above the market average72.27% above the market average72.27% above the market average72.27% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 6
Buy 2
Neutral 1
Sell 0
Strong Sell 0
Total 9
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Final Interim
Ex-Div 12-Nov-26 05-Mar-26
Paid 04-Dec-26 27-Mar-26
Amount 24.00p 11.20p

Trades for 09-Oct-2026

Time Volume / Share Price
16:37 504 @ 2,280.00p
16:37 504 @ 2,280.00p
16:36 504 @ 2,280.00p
16:35 190 @ 2,280.00p
16:35 149 @ 2,280.00p

Genus Key Personnel

CEO Jorgen Kokke
CFO Andy Russell

Top of Page